Exicure, Inc.
http://www.exicuretx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Exicure, Inc.
Ipsen Seeks Success Outside Big Pharma's Hunting Grounds
David Loew has assembled a strong business development team which secured seven licensing pacts in 2021 and the Ipsen CEO tells Scrip that this year should see more of the same.
J.P. Morgan Day 4: Preparing For The Year Ahead
Daily notebook from the virtual J.P. Morgan Healthcare Conference: Updates from Galapagos, Ipsen, LG Chem and Hanmi; experts discuss deal and financial outlook at Biotech Showcase, plus the impact of RMAT and the changing landscape for rare diseases.
J.P. Morgan Day 4: Preparing For The Year Ahead
Daily notebook from the virtual J.P. Morgan Healthcare Conference: Updates from Galapagos, Ipsen, LG Chem, Hanmi and Fosun; experts discuss deal and financial outlook at Biotech Showcase, plus the impact of RMAT and the changing landscape for rare diseases.
Deal Watch: Seagen Ups Presence In HER2-Positive Cancer Field With RemeGen Deal
Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
-
- AuraSense Therapeutics, LLC
- AuraSense Therapeutics, Inc.
- Exicure OpCo
- Max-1 Acquisition Corporation